Diabetes care HbA1c converter tools are essential for anyone managing diabetes in the UK, where results are reported in mmol/mol rather than the older percentage (%) scale. HbA1c — glycated haemoglobin — reflects your average blood glucose over the preceding two to three months and is central to monitoring diabetes control and guiding treatment decisions. Whether you are interpreting NHS results, reviewing older records, or reading international research, understanding how to convert between mmol/mol and % is a practical skill. This article explains what HbA1c measures, how to convert between units, and what NICE-recommended targets mean for your care.

What Is HbA1c and Why It Matters in Diabetes Care

HbA1c measures the proportion of glycated haemoglobin in red blood cells, reflecting average blood glucose over roughly two to three months and guiding diabetes treatment decisions. Elevated levels are associated with serious complications including cardiovascular disease, retinopathy, nephropathy, and neuropathy.

HbA1c, or glycated haemoglobin, is one of the most important blood tests used in diabetes care. It measures the proportion of haemoglobin — the oxygen-carrying protein in red blood cells — that has glucose attached to it. Because red blood cells survive for approximately 120 days, the HbA1c result reflects your average blood glucose level over roughly the preceding two to three months, rather than a single point-in-time reading. It is worth noting that more recent weeks contribute proportionally more to the result than earlier weeks within that period.

HbA1c reflects longer-term glycaemia and complements other tests such as fasting plasma glucose (FPG) and the oral glucose tolerance test (OGTT); each has its own advantages and limitations, and clinicians choose between them based on individual circumstances. For people living with type 1 or type 2 diabetes, regular HbA1c monitoring helps clinicians assess how well blood glucose is being managed and whether current treatment is effective.

In line with NICE guidance (NG28, NG17), HbA1c should be measured every three to six months until levels are stable and treatment is established, and at least every six months thereafter. More frequent testing may be appropriate following treatment changes or if control is unstable.

Elevated HbA1c levels are associated with an increased risk of serious diabetes-related complications, including:

• Cardiovascular disease (heart attack and stroke)

• Diabetic retinopathy (damage to the retina)

• Diabetic nephropathy (kidney disease)

• Peripheral neuropathy (nerve damage, particularly in the feet)

Maintaining HbA1c within an agreed target range significantly reduces the risk of these complications, as demonstrated by landmark studies including the UK Prospective Diabetes Study (UKPDS 33 and 35). Understanding your HbA1c result — and knowing how to interpret the units in which it is reported — is therefore a fundamental part of effective diabetes self-management.

Important: when HbA1c may be unreliable or should not be used HbA1c can give inaccurate results in certain situations. It should not be used for diagnosis, and interpreted with caution, in the following circumstances:

• Pregnancy (use FPG or OGTT instead; see NICE NG3)

• Children and young people

• Suspected type 1 diabetes or rapidly developing hyperglycaemia (use plasma glucose)

• Haemoglobinopathies (e.g., sickle cell disease, thalassaemia) and haemolytic anaemias

• Iron deficiency anaemia or other conditions affecting red cell turnover

• Recent blood transfusion or significant blood loss

• Chronic kidney disease (CKD) or end-stage renal disease

• Certain medicines (e.g., some antiretroviral therapies)

In these situations, your healthcare team will use alternative tests — such as FPG, OGTT, or continuous glucose monitoring (CGM) — to assess glycaemic control.

Understanding HbA1c Units: mmol/mol and % Explained

Since June 2011, NHS laboratories report HbA1c in mmol/mol (IFCC), replacing the older percentage (DCCT/NGSP) scale still used in the US and older UK records. Both units measure the same thing but use different mathematical scales, making a reliable converter essential.

If you have been managing diabetes for some years, you may have noticed that HbA1c results are now reported differently than they once were. Prior to 2011, HbA1c in the UK was expressed as a percentage (%), based on the Diabetes Control and Complications Trial (DCCT/NGSP) reference standard. Since June 2011, NHS laboratories have adopted the International Federation of Clinical Chemistry (IFCC) standardised unit, which expresses HbA1c in millimoles per mole (mmol/mol).

The two units measure the same thing — the proportion of glycated haemoglobin — but use different mathematical scales:

• mmol/mol (IFCC): The current standard used across NHS laboratories and the unit used in NICE guidance. This unit is considered more precise and reproducible across different laboratories.

• % (DCCT/NGSP): The older percentage-based system, still widely used in the United States and in older UK literature. Many patients and some healthcare resources continue to refer to this scale.

Both units remain in common use globally, which is why a reliable diabetes care HbA1c converter is a practical tool for patients and clinicians alike — particularly when interpreting results from international studies, older medical records, or overseas healthcare providers.

Neither unit is inherently superior in terms of clinical meaning; they simply represent different ways of expressing the same measurement. However, because NHS laboratories now report exclusively in mmol/mol, it is important that patients understand this unit when reviewing their results. Confusion between the two scales can occasionally lead to misinterpretation — for example, an HbA1c of 53 mmol/mol is not the same as 53%, and conflating the two could cause unnecessary concern or false reassurance.

(Sources: IFCC/NGSP HbA1c standardisation; NHS HbA1c information; Diabetes UK)

How to Convert HbA1c Between mmol/mol and Percentage

Convert mmol/mol to % using: NGSP (%) = (0.09148 × IFCC mmol/mol) + 2.152; reverse the formula to convert % to mmol/mol. Key reference points include 48 mmol/mol = 6.5% (diagnostic threshold) and 53 mmol/mol = 7.0% (hypoglycaemia-risk treatment target).

Converting between mmol/mol and percentage is straightforward once you understand the underlying formula. The relationship between the two units is linear, and the following standardised IFCC/NGSP master equations are used:

To convert mmol/mol to %: NGSP (%) = (0.09148 × IFCC mmol/mol) + 2.152

To convert % to mmol/mol: IFCC (mmol/mol) = (NGSP % − 2.152) ÷ 0.09148

For everyday clinical use, most people find it easier to refer to a conversion table or an online diabetes care HbA1c converter rather than performing manual calculations. Below are some commonly referenced values to illustrate the relationship:

• Below 42 mmol/mol (< 6.0%) — below the threshold for non-diabetic hyperglycaemia (laboratory reference ranges may vary slightly)

• 42 mmol/mol = 6.0% — lower threshold of non-diabetic hyperglycaemia

• 47 mmol/mol = 6.4% — upper threshold of non-diabetic hyperglycaemia

• 48 mmol/mol = 6.5% — diagnostic threshold for type 2 diabetes; also a treatment target for many adults

• 53 mmol/mol = 7.0% — treatment target typically used when medicines carry a risk of hypoglycaemia (e.g., sulphonylureas, insulin)

• 58 mmol/mol = 7.5%

• 64 mmol/mol = 8.0%

• 75 mmol/mol = 9.0%

These reference points are particularly useful when reading clinical trial data, international guidelines, or older patient records that use the percentage scale. Many NHS patient-facing resources and diabetes charities such as Diabetes UK provide free online converters to assist with this.

It is important to remember that while conversion tools are helpful for understanding results, any concerns about your HbA1c level should always be discussed with your GP, diabetes nurse, or specialist. Self-interpreting results without clinical context — particularly if you are considering adjusting medication — carries patient safety risks and should be avoided. A converted figure is only meaningful when considered alongside your individual treatment targets, medical history, and overall diabetes management plan.

(Sources: IFCC/NGSP HbA1c master equations; NICE NG28; Diabetes UK conversion tools)

NICE and NHS HbA1c Targets for People With Diabetes

NICE recommends 48 mmol/mol (6.5%) for type 2 diabetes managed without hypoglycaemic drugs, and 53 mmol/mol (7.0%) for those on sulphonylureas or insulin (NG28). Targets are individualised; 42–47 mmol/mol indicates non-diabetic hyperglycaemia requiring monitoring and lifestyle intervention.

NICE provides clear, evidence-based HbA1c targets for people with diabetes, though these are individualised according to the type of diabetes, treatment regimen, and personal circumstances. Targets are not one-size-fits-all; what is appropriate for one person may not be suitable for another.

For type 2 diabetes (NICE guideline NG28):

• 48 mmol/mol (6.5%) is the recommended target for adults managed by lifestyle intervention or a single non-hypoglycaemic drug (e.g., metformin).

• 53 mmol/mol (7.0%) is the target for those on drugs that carry a risk of hypoglycaemia, such as sulphonylureas or insulin.

• If HbA1c rises to 58 mmol/mol (7.5%) or above despite treatment, NICE recommends intensifying therapy.

For type 1 diabetes (NICE guideline NG17):

• NICE recommends a target of 48 mmol/mol (6.5%) for adults with type 1 diabetes, acknowledging that this must be balanced against the risk of hypoglycaemia.

• Targets may be relaxed in individuals with hypoglycaemia unawareness, significant comorbidities, or limited life expectancy.

Diagnostic thresholds:

• An HbA1c of 48 mmol/mol (6.5%) or above on two separate occasions is diagnostic of type 2 diabetes in asymptomatic individuals (a single result is sufficient if symptoms are present).

• An HbA1c of 42–47 mmol/mol (6.0–6.4%) indicates non-diabetic hyperglycaemia (sometimes called prediabetes), which carries an elevated risk of progression to type 2 diabetes.

When HbA1c should not be used for diagnosis: HbA1c is not appropriate for diagnosing diabetes in pregnancy, in children, in suspected type 1 diabetes, or in conditions affecting red cell turnover (see the first section for a full list). In these situations, plasma glucose testing (FPG or OGTT) should be used instead (NICE NG3, NG17).

Urgent symptoms — seek same-day medical assessment: If you or someone you know experiences symptoms that may suggest type 1 diabetes, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycaemic state (HHS) — including excessive thirst, frequent urination, unexplained weight loss, vomiting, abdominal pain, drowsiness, deep or laboured breathing, or confusion — do not wait for an HbA1c result. Seek same-day urgent medical assessment by calling 999 or attending your nearest emergency department.

Not sure if this is normal? Chat with one of our pharmacists →

NICE also emphasises that HbA1c targets should be agreed collaboratively between the patient and their healthcare team, taking into account quality of life, treatment burden, and individual risk factors. Overly aggressive targets in elderly or frail patients, for example, may increase the risk of hypoglycaemia without meaningful benefit.

(Sources: NICE NG28; NICE NG17; NICE NG3; NHS HbA1c information; OHID/PHE non-diabetic hyperglycaemia guidance)

What Your HbA1c Result Means for Your Treatment Plan

An above-target HbA1c may prompt lifestyle review, medication intensification, or structured education referral in line with NICE NG28 or NG17. An unexpectedly low result may signal hypoglycaemia risk or a condition affecting red cell turnover, both requiring clinical review.

Receiving an HbA1c result can feel daunting, particularly if it is higher than expected. However, it is important to view the result as a useful clinical tool rather than a judgement — it provides actionable information that can guide positive changes to your treatment and lifestyle.

If your HbA1c is within your agreed target range, this is a positive sign that your current management plan is working. Your healthcare team will typically continue your existing treatment and schedule a routine review. Maintaining good control over time significantly reduces your long-term risk of complications.

If your HbA1c is above your target, your GP or diabetes team may consider several options depending on your individual circumstances:

• Lifestyle modifications: Reviewing diet, physical activity levels, and weight management, which remain the cornerstone of type 2 diabetes care.

• Medication adjustment: Adding or intensifying pharmacological therapy in line with NICE NG28 guidance — for example, adding an SGLT-2 inhibitor, GLP-1 receptor agonist, or insulin.

• Structured education: For type 2 diabetes, referral to programmes such as DESMOND or X-PERT supports self-management skills. For type 1 diabetes, DAFNE (Dose Adjustment For Normal Eating) is a NICE-recommended structured education programme (NICE NG17). The NHS Diabetes Prevention Programme (NHS DPP) is designed for people with non-diabetic hyperglycaemia (42–47 mmol/mol) who are at high risk of developing type 2 diabetes; it is not intended for people who already have a diagnosis of type 2 diabetes.

If your HbA1c is unexpectedly low, this may occasionally indicate a risk of hypoglycaemia, particularly in those on insulin or sulphonylureas, and warrants a clinical review to assess whether treatment should be de-intensified. An unexpectedly low result may also reflect a condition affecting red cell turnover (such as anaemia, haemolysis, or recent transfusion) rather than true glycaemic improvement; your healthcare team can advise on whether further investigation is needed.

When to contact your GP or diabetes team:

• Your HbA1c has risen significantly since your last test

• You are experiencing symptoms of hypoglycaemia (shakiness, sweating, pallor, confusion, palpitations)

• You have recently started a new medication and are unsure of its effect

• You are pregnant or planning a pregnancy — early referral to a specialist diabetes in pregnancy team is recommended, as tighter targets and closer monitoring apply (NICE NG3)

• You have a foot ulcer, wound, or infection — seek urgent review from your podiatry or diabetes team

Urgent symptoms — act immediately: Symptoms suggestive of DKA or HHS (excessive thirst, frequent urination, unexplained weight loss, vomiting, abdominal pain, drowsiness, deep or laboured breathing, confusion) require same-day emergency assessment. Call 999 or go to your nearest emergency department without delay.

Reporting side effects: If you experience a suspected side effect from any diabetes medicine — including hypoglycaemia — you can report this to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme at yellowcard.mhra.gov.uk. Your report helps improve the safety of medicines for everyone.

Experiencing these side effects? Our pharmacists can help you navigate them →

Using a diabetes care HbA1c converter helps you understand your results in context, but always discuss any concerns with a qualified healthcare professional before making changes to your treatment.

(Sources: NICE NG28; NICE NG17; NICE NG3; OHID/PHE NHS DPP eligibility guidance; MHRA Yellow Card Scheme)

Frequently Asked Questions